© Reuters. FILE PHOTO: Normal view reveals the laboratories of BioNTech at their COVID-19 vaccine manufacturing facility because the unfold of the coronavirus illness (COVID-19) continues, in Marburg, Germany, March 27, 2021. REUTERS/Kai Pfaffenbach/File Picture
FRANKFURT (Reuters) – Pharma-Park Marburg, the place German drugmaker BioNTech produces its COVID-19 vaccine, has been put up on the market in a possible 450 million euro ($531 million) deal, three folks near the matter mentioned.
The biotech-focused industrial park, which additionally counts GSK, Healthineers and CSL (OTC:) Behring as tenants, has been supplied on the market by its proprietor Infrareal, they mentioned.
Insurer Swiss Life and infrastructure investor Ancala are anticipated to submit binding bids in coming days, the folks added.
Infrareal and Ancala weren’t instantly out there for remark, whereas Swiss Life declined to remark.
Pharma-Park Marburg has annual earnings earlier than curiosity, tax, depreciation and amortisation of about 25 million euros and may very well be valued at 400-450 million euros, the folks mentioned.
The commercial park covers an space of 67.4 hectares, and roughly 6,000 workers work there.
($1 = 0.8481 euros)
Fusion Media or anybody concerned with Fusion Media won’t settle for any legal responsibility for loss or harm on account of reliance on the data together with information, quotes, charts and purchase/promote alerts contained inside this web site. Please be totally knowledgeable relating to the dangers and prices related to buying and selling the monetary markets, it is without doubt one of the riskiest funding varieties potential.